GBS vs. CTCX, DRIO, XAIR, APYX, NSPR, DXR, LNSR, CODX, CTSO, and LUCD
Should you be buying GBS stock or one of its competitors? The main competitors of GBS include Carmell (CTCX), DarioHealth (DRIO), Beyond Air (XAIR), Apyx Medical (APYX), InspireMD (NSPR), Daxor (DXR), LENSAR (LNSR), Co-Diagnostics (CODX), Cytosorbents (CTSO), and Lucid Diagnostics (LUCD). These companies are all part of the "surgical & medical instruments" industry.
GBS (NYSE:GBS) and Carmell (NASDAQ:CTCX) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, community ranking, valuation, institutional ownership, dividends, earnings, profitability, media sentiment and risk.
GBS has a beta of 1.32, indicating that its stock price is 32% more volatile than the S&P 500. Comparatively, Carmell has a beta of 0.32, indicating that its stock price is 68% less volatile than the S&P 500.
GBS's return on equity of -85.64% beat Carmell's return on equity.
GBS and Carmell both received 0 outperform votes by MarketBeat users.
GBS has higher revenue and earnings than Carmell.
In the previous week, GBS had 4 more articles in the media than Carmell. MarketBeat recorded 6 mentions for GBS and 2 mentions for Carmell. Carmell's average media sentiment score of -0.16 beat GBS's score of -0.26 indicating that Carmell is being referred to more favorably in the news media.
2.8% of GBS shares are owned by institutional investors. Comparatively, 24.2% of Carmell shares are owned by institutional investors. 0.3% of GBS shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
Summary
GBS beats Carmell on 6 of the 9 factors compared between the two stocks.
Get GBS News Delivered to You Automatically
Sign up to receive the latest news and ratings for GBS and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GBS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Related Companies and Tools
